phosphorylcholine has been researched along with Inflammatory Bowel Diseases in 2 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Inflammatory Bowel Diseases: Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We assessed the therapeutic potential of tuftsin-PC conjugate (TPC) to attenuate murine colitis." | 7.81 | Phosphorylcholine-tuftsin compound prevents development of dextransulfate-sodium-salt induced murine colitis: implications for the treatment of human inflammatory bowel disease. ( Barshak, I; Bashi, T; Ben-Ami Shor, D; Bizzaro, G; Blank, M; Fridkin, M; Lachnish, J; Shoenfeld, Y, 2015) |
| "Miltefosine inhibits T-cell proliferation and effectively reduces inflammation in the T-cell transfer model." | 7.79 | Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease. ( Duijvestein, M; Hommes, DW; Meijer, SL; Peppelenbosch, MP; te Velde, AA; van den Brink, GR; Verhaar, AP; Vos, AC; Wildenberg, ME, 2013) |
| " We assessed the therapeutic potential of tuftsin-PC conjugate (TPC) to attenuate murine colitis." | 3.81 | Phosphorylcholine-tuftsin compound prevents development of dextransulfate-sodium-salt induced murine colitis: implications for the treatment of human inflammatory bowel disease. ( Barshak, I; Bashi, T; Ben-Ami Shor, D; Bizzaro, G; Blank, M; Fridkin, M; Lachnish, J; Shoenfeld, Y, 2015) |
| "Miltefosine inhibits T-cell proliferation and effectively reduces inflammation in the T-cell transfer model." | 3.79 | Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease. ( Duijvestein, M; Hommes, DW; Meijer, SL; Peppelenbosch, MP; te Velde, AA; van den Brink, GR; Verhaar, AP; Vos, AC; Wildenberg, ME, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Verhaar, AP | 1 |
| Wildenberg, ME | 1 |
| te Velde, AA | 1 |
| Meijer, SL | 1 |
| Vos, AC | 1 |
| Duijvestein, M | 1 |
| Peppelenbosch, MP | 1 |
| Hommes, DW | 1 |
| van den Brink, GR | 1 |
| Ben-Ami Shor, D | 1 |
| Bashi, T | 1 |
| Lachnish, J | 1 |
| Fridkin, M | 1 |
| Bizzaro, G | 1 |
| Barshak, I | 1 |
| Blank, M | 1 |
| Shoenfeld, Y | 1 |
2 other studies available for phosphorylcholine and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cytokines; Disease Models, Animal; Humans; Immun | 2013 |
Phosphorylcholine-tuftsin compound prevents development of dextransulfate-sodium-salt induced murine colitis: implications for the treatment of human inflammatory bowel disease.
Topics: Animals; Colitis; Cytokines; Dextran Sulfate; Disease Models, Animal; Humans; Immunologic Factors; I | 2015 |